Rahul Singhvi

CIK 1322731 · President, CEO · last filed 2025-11-26

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.08M

Companies

4

Total Filings

19

Lifetime Open-Market Net

-$769.5K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KAPA Director 49,204 $0.44 $21.6K $0 1 2025-11-26
CDXS Director 137,052 $2.40 $328.9K $0 5 2025-06-12
ImmunoCellular Therapeutics, Ltd. (IMUC) Delisted Director 15,000 $0 5 2016-06-21
NVAX President, CEO 194,838 $8.88 $1.73M -$769.5K 8 2011-03-14

Recent Filings · Page 2 of 2

19 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2012-12-18 ImmunoCellular Therapeutics, Ltd. (IMUC) Delisted Grant (A) $0 EDGAR
2011-03-14 NVAX Grant (A) $0 EDGAR
2010-03-17 NVAX Grant (A) $0 EDGAR
2009-07-06 NVAX Mixed −108,334 -$661.9K EDGAR
2009-03-09 NVAX Grant (A) $0 EDGAR
2008-08-04 NVAX Buy (P) +10,554 $0 EDGAR
2008-03-10 NVAX Grant (A) $0 EDGAR
2007-08-29 NVAX Buy (P) +1,100 $3.3K EDGAR
2007-03-09 NVAX Grant (A) $0 EDGAR
Showing 1119 of 19
Page 2 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.